Evidence map›Paper›PMID 26202415›Full record

ArticleHepatology international2014

Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience.

Εvangelos Cholongitas, Ioannis Goulis, Eleni Theocharidou, Nikolaos Antoniadis, Ioannis Fouzas, Dimitrios Giakoustidis, George Imvrios, Olga Giouleme, Vasilios Papanikolaou, Evangelos Akriviadis and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Use of everolimus in liver transplantation.World journal of hepatology · 2017
    Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Εvangelos Cholongitas4th Department of Internal Medicine, Hippokration General Hospital of Thessaloniki, Medical School of Aristotle University, 49, Konstantinopoleos Street, 54642, Thessaloniki, Greece. cholongitas@yahoo.gr.
Ioannis Goulis4th Department of Internal Medicine, Hippokration General Hospital of Thessaloniki, Medical School of Aristotle University, 49, Konstantinopoleos Street, 54642, Thessaloniki, Greece.
Eleni Theocharidou2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Medical School of Aristotle University, Thessaloniki, Greece.
Nikolaos AntoniadisDepartment of Transplant Surgery, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Ioannis FouzasDepartment of Transplant Surgery, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Dimitrios GiakoustidisDepartment of Transplant Surgery, Aristotle University of Thessaloniki, Thessaloniki, Greece.
George ImvriosDepartment of Transplant Surgery, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Olga Giouleme2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Medical School of Aristotle University, Thessaloniki, Greece.
Vasilios PapanikolaouDepartment of Transplant Surgery, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Evangelos Akriviadis4th Department of Internal Medicine, Hippokration General Hospital of Thessaloniki, Medical School of Aristotle University, 49, Konstantinopoleos Street, 54642, Thessaloniki, Greece.
Themistoklis Vasiliadis1st Propedeutic Department of Internal Medicine, AHEPA General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Aristotle University of Thessaloniki · GRHippocration General Hospital · GRIppokrateio General Hospital of Thessaloniki · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEverolimus, a mammalian target of rapamycin inhibitor, has been shown to reduce growth factor-mediated cell proliferation, but data regarding its effectiveness and impact on renal function and recurrence of hepatocellular carcinoma (HCC) in liver transplant (LT) recipients are limited.

methodsWe evaluated LT recipients with a calcineurin inhibitor (CNI)-based immunosuppression regimen in whom everolimus treatment was initiated. The changes in laboratory data, including glomerular filtration rate (GFR), compared to the baseline (i.e. the day of everolimus conversion), were assessed.

resultsTotally, 44 consecutive patients (32 men, age 55 ± 7 years) were commenced on everolimus [indications: renal dysfunction post-LT (16 patients, group 1); prevention of HCC recurrence (21 patients) or others (7 patients), group 2] at 6 months (range 1-206) post-LT. After 48 (range 12-76) months, all patients were alive without any rejection episodes. Compared to group 2 patients, group 1 patients had significantly greater improvement in renal function (DGFR: 12 ± 5 vs. -0.4 ± 0.2 ml/min, p = 0.02). GFR at baseline (OR 0.08, p = 0.002) and the combination of everolimus + MMF (OR 0.14, p = 0.024) were the factors independently associated with improvement in renal function. Finally, HCC recurrence was observed less frequently in the everolimus group of patients (n = 21) compared to the CNI-historical control group (n = 22) with HCC before LT [0/21 (0 %) vs. 4/22 (18.5 %), log rank p = 0.055), although the two groups of recipients had similar baseline characteristics and follow-up.

conclusionsEverolimus is effective and is associated with low rates of HCC recurrence and improvement of renal function in LT recipients.

Indexed as

EverolimusHepatocellular carcinomaLiver transplantationMammalian target of rapamycin inhibitorRenal function

Identifiers

PMID26202415
OpenAlexW2091960470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.